Curiox Biosystems and ϳԹ Announce Method to Safely Prepare COVID-19 Blood Samples for Vaccine Research
Curiox Biosystems, in conjunction with ϳԹ, developed a new system that will help researchers develop vaccines for SARS-CoV-2
03/30/2020
Curiox Biosystems in conjunction with ϳԹ today announced a new system that will help researchers develop vaccines to , the virus that causes COVID-19.
A new configuration of the Laminar Wash™ HT1000 System will allow scientists to completely process blood samples from COVID-19 positive patients in a safe environment. The package will consist of an updated Laminar Wash HT1000 system, Buffer Exchanger, and ϳԹ’ EasySep™ RBC Depletion Reagent.
enables researchers to more accurately study immune responses for vaccine research and clinical trials without the need for centrifugation, eliminating the aerosolization of potentially infectious samples. Laminar Wash technology is especially helpful in . The new HT1000 configuration allows containment of blood samples within a biosafety cabinet, ensuring the protection of laboratory staff and other samples.
“We are always aspiring to help scientists perform their research in a more accurate and safe manner” said Dr. Namyong Kim, CEO of Curiox Biosystems.
Traditionally, unwanted red blood cells (RBCs) are removed from blood samples using lysis buffers, which can be harmful to white blood cells, the cells responsible for immune response. By working with ϳԹ’ RBC depletion kits, researchers can easily remove unwanted RBCs from blood samples without the need for lysis, resulting in superior data quality.
“It is always a proud moment when the reagents and tools we develop can help enable scientific discoveries and treatments. This new application will facilitate the safe processing of blood samples so that researchers can better understand the immune response to current and future infectious disease outbreaks” said Dr. Andy Kokaji, Director of Immunology at ϳԹ.
Enabling safe and efficient handling of virus-positive blood samples ultimately helps patients by accelerating treatment and vaccine research. The new package of products is available starting, March 23, 2020. Curiox and ϳԹ are offering to assist institutions in obtaining the product as easily as possible, with donations considered in some cases.
About Curiox Biosystems
Curiox Biosystems is a bioinstrumentation company spun out of the Agency for Science, Technology, and Research (A*STAR) in Singapore. Curiox has become a leader in the development and commercialization of innovative assay platforms based on its expertise in surface chemistry and engineering. Curiox’s vision is to accelerate the progress of life sciences, drug discovery and diagnostics through the miniaturization and improved automation of bioassays.
About ϳԹ
ϳԹ is Canada’s largest biotechnology company. ϳԹ supports life sciences research with high-quality cell culture media, cell separation technologies, instruments, accessory products, and educational resources. ϳԹ’s products are used globally by scientists advancing the stem cell, immunology, cancer, regenerative medicine, microbiology, and cellular therapy fields. Find more information at www.stemcell.com
Source:
Latest ϳԹ News
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to ϳԹ Canada Inc. and its subsidiaries and affiliates (“ϳԹ”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
